Resumen documental de ASEM
Official Canadian Paediatric Society document (2024) on “Respiratory syncytial virus (RSV) prevention strategies for the 2024-2025 viral respiratory illness season”. Prevention of respiratory syncytial virus (RSV) infection in young children, particularly those at highest risk of severe illness, is an important public health goal. Previously, palivuzimab was the only preventative agent available in Canada but recently, two new agents have been approved for use. This paper provides a brief review of the National Advisory Committee on Immunization (NACI)’s latest recommendations fo.
Este resumen facilita la identificación del documento. Para consultar recomendaciones clínicas, consulte siempre la versión oficial vigente y su fecha de actualización.
Documento oficial